Europe Non-Alcoholic Steatopatitis Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)

No. of Pages: 128    |    Report Code: BMIRE00025404    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Non-Alcoholic Steatopatitis Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Europe Non-Alcoholic Steatopatitis Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Europe Non-Alcoholic Steatopatitis Market – Key Market Dynamics

5.1 Growth Drivers
5.2 Market Opportunities
5.3 Future Trends
5.4 Impact of Drivers and Restraints

6. Europe Non-Alcoholic Steatopatitis Market Regional Analysis

6.1 Europe Non-Alcoholic Steatopatitis Market Overview
6.2 Europe Non-Alcoholic Steatopatitis Market Revenue 2019-2028 (US$ Million)
6.3 Europe Non-Alcoholic Steatopatitis Market Forecast Analysis

7. Europe Non-Alcoholic Steatopatitis Market Analysis – by Product

7.1 Vitamin E and Pioglitazone
  • 7.1.1 Overview
  • 7.1.2 Vitamin E and Pioglitazone: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Ocaliva
  • 7.2.1 Overview
  • 7.2.2 Ocaliva: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Elafibranor
  • 7.3.1 Overview
  • 7.3.2 Elafibranor: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Selonsertib
  • 7.4.1 Overview
  • 7.4.2 Selonsertib: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Cenicriviroc
  • 7.5.1 Overview
  • 7.5.2 Cenicriviroc: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Non-Alcoholic Steatopatitis Market Analysis – by Application

8.1 Treatment
  • 8.1.1 Overview
  • 8.1.2 Treatment: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Diagnosis
  • 8.2.1 Overview
  • 8.2.2 Diagnosis: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Non-Alcoholic Steatopatitis Market Analysis – by Sales Channel

9.1 Hospital Pharmacy
  • 9.1.1 Overview
  • 9.1.2 Diagnosis: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Online Provider
  • 9.2.1 Overview
  • 9.2.2 Diagnosis: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Retail Pharmacy
  • 9.3.1 Overview
  • 9.3.2 Diagnosis: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Non-Alcoholic Steatopatitis Market – Europe Analysis

10.1 Europe
  • 10.1.1 Europe Non-Alcoholic Steatopatitis Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 UK: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 UK: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Product
    • 10.1.1.1.2 UK: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Application
    • 10.1.1.1.3 UK: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Sales Channel
  • 10.1.1.2 Germany: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Germany: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Product
    • 10.1.1.2.2 Germany: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Application
    • 10.1.1.2.3 Germany: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Sales Channel
  • 10.1.1.3 France: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 France: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Product
    • 10.1.1.3.2 France: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Application
    • 10.1.1.3.3 France: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Sales Channel
  • 10.1.1.4 Russia: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Russia: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Product
    • 10.1.1.4.2 Russia: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Application
    • 10.1.1.4.3 Russia: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Sales Channel
  • 10.1.1.5 Italy: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.5.1 Italy: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Product
    • 10.1.1.5.2 Italy: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Application
    • 10.1.1.5.3 Italy: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Sales Channel
  • 10.1.1.6 Rest of Europe: Europe Non-Alcoholic Steatopatitis Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.6.1 Rest of Europe: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Product
    • 10.1.1.6.2 Rest of Europe: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Application
    • 10.1.1.6.3 Rest of Europe: Europe Non-Alcoholic Steatopatitis Market Breakdown, by Sales Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Europe Non-Alcoholic Steatopatitis Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Cadila Pharmaceutical.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Intercept Pharmaceutical.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Novartis AG.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Galmed Pharmaceutical.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 GENFIT.
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 ONE WAY LIVER SI.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 BioPredictive S.A.S.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Siemens Healthineers AG.
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Laboratory Corporation of America Holdings.
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - E Market

  1. Cadila Pharmaceutical.
  2. Intercept Pharmaceutical.
  3. Novartis AG.
  4. Galmed Pharmaceutical.
  5. GENFIT.
  6. ONE WAY LIVER SI.
  7. BioPredictive S.A.S.
  8. Siemens Healthineers AG.
  9. Laboratory Corporation of America Holdings.            
europe-non-alcoholic-steatopatitis-market